| - Sale of product for the first six months of 2025 increased 13.5% or $820,529
- Net Income (Loss) the first six months of 2025 improved 29% to a loss of $273,479
- Non-GAAP EBITDA(1) the first six months of 2025 improved 151% or $142,091
IDAHO FALLS, Idaho, Aug. 13, 2025 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") is pleased to announce its financial results for the second quarter and six months ended June 30, 2025. Revenue from the sale of product for the second quarter of 2025 was $3,655,320, an increase of $486,087 or 15.3%, compared to the same period in the prior year, and for the six months ended June 30, 2025 was $6,894,220, an increase of $820,529 or 13.5% from the same period in the prior year. Net loss for the second quarter of 2025 improved to $160,785 from a loss of $233,445 in the same period last year, a 27% increase, and for the first six months of 2025 improved to $273,479, a 29.4% improvement from the same period in the prior year. Non-GAAP EBITDA(1) increased to $1,199 in the second quarter of 2025, an increase of $85,202, and non-GAAP EBITDA(1) for the first six months of 2025 improved to $51,569, a 157% improvement from the same period in the prior year. The Company also reported a non-GAAP adjusted EBITDA(1) of $39,114 for the second quarter of 2025 and $174,020 for the first six months of 2025. Increases for the six months ended June 30, 2025 were driven primarily by growth of sales of Nuclear Medicine Standards products and Cobalt product sales, partially offset by a decrease in sales of Theranostics products compared to the same period in the prior year. (1) See "Non-GAAP Financial Measures" below. Shahe Bagerdjian, President & CEO of the Company, said, "We are happy with our growth of sales, ending this quarter with a 15% increase and 13.5% growth for the first half compared to last year. We still anticipate a solid 2nd half of 2025 due to increased seasonal sales of Cobalt products, and the launch of new products. " Segment Results Theranostics Products
Revenue from the sale of Theranostics Products for the first six months of 2025 was $3,692,233, compared to $4,074,213 for the same period in the prior year. This is a decrease of $381,757 or 9% compared to the same period in the prior year, primarily due to a loss of some standing order customers. In the second quarter of 2025, the Company received US FDA approval to add an additional raw material supplier. We continue to see demand for generic sodium iodide I-131 pharmaceutical and I-131 theranostic API products, which are used in radiolabeling third party drug products. Nuclear Medicine Standards
Revenue from the sale of Nuclear Medicine Standards products for the first six months of 2025 was $2,340,580, compared to $1,173,311 for the same period in the prior year. This represents an increase of $1,167,269 or 99%, compared to the same period in the prior year, primarily due to remedying of the global shortage of Cobalt-57 isotope, which lasted from January 2024 to late July 2024. Additionally, our Nuclear Medicine Standards segment continues to be impacted by an on-going global outage of Gd-153, which is the raw material in the Company's key products, BM53 line sources. We expect full year 2025 revenues in this segment to reflect historically normal amounts as the supply chain has normalized, and we continue to launch new products under our RadQual and PhanQual brands. Cobalt Products
Revenue from the sale of Cobalt Products for the first six months of 2025 was $750,465, compared to $826,167 for the same period in the prior year. This represents a decrease of $75,702 or 9%, compared to the same period in the prior year, primarily due to timing of sales over the course of the last 12 months. Large value sales of high activity Cobalt-60 sources are seasonal and occur at various times throughout the year. Frequently the timing of these sales can have a significant impact on period comparisons. Fiscal 2024 marked a historical high in Cobalt Product sales for the Company. The Company remains the only domestic United States manufacturer of high activity Cobalt-60 sealed-source products. We anticipate sales of Cobalt products for the rest of 2025 to be strong based on planned production and sales in the third quarter of 2025. Medical Devices
Revenue from the sale of Medical Device products for the first six months of 2025 was $58,089, compared to no sales for the same period in the prior year. Medical Devices was a new reportable business segment for fiscal year 2024. We have invested in this segment throughout the past three years and anticipate additional investments in the rest of 2025 as we ramp to commercialization of products. This segment includes The Swirler® and Tru-Fit™ Mouthpiece, Xenon System, and related accessories under the RadVent brand as well as partnering with leading manufacturers for distribution through our network of global distributors. Additionally, the Company invested in a joint venture arrangement for our EasyFill Automated Iodine Capsule System, which recently signed an exclusive distribution and servicing agreement for the full line of Scintomics ATT products. The Medical Device segment is focused on bringing products to market which help the industry improve safety, efficiency, and patient access to radiopharmaceutical diagnostics and therapeutics.
| Three Months Ended June 30, 2025 |
| Six Months Ended June 30, 2025 |
| 2025 | 2024 | $ Change | %
Change |
| 2025 | 2024 | $ Change | %
Change | Sale of product | $ | 3,655,320 | $ | 3,169,233 | $ | 486,087 | 15.3 % |
| $ | 6,894,220 | $ | 6,073,691 | $ | 820,529 | 13.5 % | Gross profit | $ | 2,141,559 | $ | 2,017,511 | $ | 124,048 | 6.1 % |
| $ | 4,173,596 | $ | 3,883,622 | $ | 289,974 | 7.5 % | Total Operating
Expense | $ | 2,276,400 | $ | 2,197,635 | $ | 78,765 | 3.6 % |
| $ | 4,373,453 | $ | 4,329,942 | $ | 43,511 | 1.0 % | Operating Profit
(Loss) Before Other
Exp | $ | (134,841) | $ | (180,124) | $ | 45,283 | 25.1 % |
| $ | (199,857) | $ | (446,320) | $ | 246,463 | 55.2 % | Other Income
(Expense) | $ | (25,944) | $ | (52,321) | $ | 27,377 | 51 % |
| $ | (73,622) | $ | 58,824 | $ | (132,466) | 225 % | Net Income (Loss) | $ | (160,785) | $ | (233,445) | $ | 72,660 | 31.1 % |
| $ | (273,479) | $ | (387,496) | $ | 114,017 | 29.4 % | Net income per
common share –
basic: | $ | — | $ | — | $ | — |
|
| $ | — | $ | — | $ | — |
| Net income per
common share –
diluted: | $ | — | $ | — | $ | — |
|
| $ | — | $ | — | $ | — |
| Weighted avg. shares
outstanding - basic |
| 527,355,415 |
| 522,779,643 |
|
|
|
|
| 525,718,720 |
| 521,473,413 |
|
|
| Weighted avg. shares
outstanding - diluted |
| 527,355,415 |
| 522,779,643 |
|
|
|
|
| 525,718,720 |
| 521,473,413 |
|
|
|
Full Earnings Release Available on INIS Website
A full version of this earnings release is available on our Investor Center website at https://intisoid.com/investor-center/. Non-GAAP Financial Measures
This press release contains financial measures that do not comply with U.S. generally accepted accounting principles ("GAAP"), such as EBITDA and Adjusted EBITDA. EBITDA is defined as net income plus interest, income taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA, adjusted to exclude items that are deemed to be unusual and non-recurring, and that we do not believe are indicative of the companies recurring operating performance, such as non-cash stock-based compensation, gain on disposal of assets, and costs associated with NRC enforcement matters and our medical devices buildout. These non-GAAP financial measures are supplemental measures to our results of operations as reported under GAAP. Our management uses these measures to better analyze our financial results and business operations. In management's opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the ongoing operating performance of the Company and its future outlook. Such measures should not be considered alternatives to net income or any other performance measures derived in accordance with GAAP. The Company's measurement of EBITDA and Adjusted EBITDA may not be comparable to similar measures of other companies as they are not performance measures calculated in accordance with GAAP. Non-GAAP Reconciliations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Three Months Ended June 30, 2025 |
| Six Months Ended June 30, 2025 |
| 2025 | 2024 | $ Change | %
Change |
| 2025 | 2024 | $ Change | %
Change | Net income (loss) | $ | (160,785) | $ | (233,445) | $ | 72,660 | 31 % |
| $ | (273,479) | $ | (387,496) | $ | 114,017 | 29 % | Interest expense, net | $ | 64,039 | $ | 47,977 | $ | 16,062 | -33 % |
| $ | 126,066 | $ | 96,552 | $ | 29,514 | -31 % | Provision for income taxes | $ | 0 | $ | 0 | $ | — | — |
| $ | 0 | $ | 0 | $ | — | — | Depreciation and amortization | $ | 97,945 | $ | 101,447 | $ | (3,502) | -3 % |
| $ | 198,982 | $ | 200,422 | $ | (1,440) | -1 % | EBITDA | $ | 1,199 | $ | (84,021) | $ | 85,220 | 101 % |
| $ | 51,569 | $ | (90,522) | $ | 142,091 | 157 % | Non-cash stock-based
compensation | $ | (4,482) | $ | 21,750 | $ | (26,232) | -121 % |
| $ | 65,797 | $ | 84,400 | $ | (18,603) | -22 % | Gain on disposal of property,
plant, and equipment | $ | 0 | $ | (13,492) | $ | — | — |
| $ | 0 | $ | (13,492) | $ | — | — | NRC Enforcement Matters(a)(1) | $ | 30,087 | $ | 157,325 | $ | (76,527) | -100 % |
| $ | 30,087 | $ | 233,852 | $ | (76,527) | -100 % | Medical Devices Buildout(b)(1) | $ | 12,310 | $ | 55,805 | $ | (43,495) | -78 % |
| $ | 26,567 | $ | 138,801 | $ | (112,234) | -81 % | Adjusted EBITDA | $ | 39,114 | $ | 137,367 | $ | (98,253) | -72 % |
| $ | 174,020 | $ | 353,039 | $ | (179,019) | -51 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (a) Represents costs for an NRC violation that occurred in 2022, including legal expenses, costs for
corrective actions, and NRC fines |
|
|
|
|
|
|
|
| (b) Represents legal work for initial buildout of the Medical Devices business segment |
|
|
|
|
|
|
|
|
International Isotopes Inc. Safe Harbor Statement
Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including its Annual Report on Form 10-K for the year ended December 31, 2024. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward- looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. About International Isotopes Inc.
International Isotopes Inc. (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. INIS manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. INIS manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under its RadQual brand. The Company also manufactures Cobalt-60 sealed source products and provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. INIS recently launched a manufacturing joint venture with Alpha Nuclides, to bring INIS and RadQual products into China via Radnostix China. The Company is working to launch its RadVent brand of medical devices in 2025, which includes the Swirler® and Tru-Fit™ product lines. For more information, visit intisoid.com.  View original content:https://www.prnewswire.com/news-releases/international-isotopes-inc-announces-fiscal-results-for-the-second-quarter-and-six-months-ended-june-30-2025-302528549.html
SOURCE International Isotopes Inc. | |
